T-cell Modulatory Properties of CD5 and Its Role in Antitumor Immune Responses

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2013 Mar 14

PMID 23483035

Citations 28

Authors

Mouna Tabbekh

Mbarka Mokrani-Hammani

Georges Bismuth

Fathia Mami-Chouaib

Affiliations

Soon will be listed here.

Abstract

The destruction of tumor cells by the immune system is under the control of positive and negative receptors that tightly regulate T-cell effector functions. The T-cell receptor (TCR) inhibitory molecule CD5 critically contributes to the regulation of antitumor immune responses. Indeed, the modulation of CD5 within the tumor microenvironment corresponds to a strategy adopted by tumor-specific cytotoxic T lymphocytes (CTLs) to optimize their cytotoxic and cytokine secretion functions. In this review, we provide insights into the immunobiology of CD5 and its role in regulating antitumor CD8 T-cell responses, and suggest the possibility of targeting CD5 to improve the efficacy of current immunotherapeutic approaches against cancer.

Citing Articles

Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma.

Breaza G, Closca R, Cindrea A, Hut F, Cretu O, Sima L Diagnostics (Basel). 2025; 15(5).

PMID: 40075893 PMC: 11899021. DOI: 10.3390/diagnostics15050646.

Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

Elghawy O, Cao M, Xu J, Landsburg D, Svoboda J, Nasta S Cancers (Basel). 2024; 16(19).

PMID: 39410047 PMC: 11476060. DOI: 10.3390/cancers16193430.

A review of CD4 T cell differentiation and diversity in dogs.

Lang H, Osum K, Friedenberg S Vet Immunol Immunopathol. 2024; 275:110816.

PMID: 39173398 PMC: 11421293. DOI: 10.1016/j.vetimm.2024.110816.

CD5 Expression Dynamically Changes During the Differentiation of Human CD8 T Cells Predicting Clinical Response to Immunotherapy.

Kim Y, Rho K, Jeong S, Lee G, Kim H, Cho H Immune Netw. 2023; 23(4):e35.

PMID: 37670812 PMC: 10475823. DOI: 10.4110/in.2023.23.e35.

Relationship Between Immunohistochemical CD3, CD4, CD5, CD8, and PD1 Staining and Histopathological Diagnosis of Cervical Lesions in Patients With Abnormal Colposcopic Findings.

Atigan A, Guler T, Karakaya Y, Kilic D Cureus. 2022; 14(11):e31399.

PMID: 36514573 PMC: 9742978. DOI: 10.7759/cureus.31399.

References

Ngiow S, Von Scheidt B, Akiba H, Yagita H, Teng M, Smyth M . Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71(10):3540-51. DOI: 10.1158/0008-5472.CAN-11-0096. View

Smith K, Seddon B, Purbhoo M, Zamoyska R, Fisher A, MERKENSCHLAGER M . Sensory adaptation in naive peripheral CD4 T cells. J Exp Med. 2001; 194(9):1253-61. PMC: 2195983. DOI: 10.1084/jem.194.9.1253. View

Alberola-Ila J, Places L, Cantrell D, Vives J, Lozano F . Intracellular events involved in CD5-induced human T cell activation and proliferation. J Immunol. 1992; 148(5):1287-93. View

van de Velde H, von Hoegen I, Luo W, Parnes J, Thielemans K . The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature. 1991; 351(6328):662-5. DOI: 10.1038/351662a0. View

Axtell R, Xu L, Barnum S, Raman C . CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system. J Immunol. 2006; 177(12):8542-9. PMC: 2744950. DOI: 10.4049/jimmunol.177.12.8542. View

Azzam H, Grinberg A, Lui K, Shen H, Shores E, Love P . CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998; 188(12):2301-11. PMC: 2212429. DOI: 10.1084/jem.188.12.2301. View

Algarra I, Cabrera T, Garrido F . The HLA crossroad in tumor immunology. Hum Immunol. 2000; 61(1):65-73. DOI: 10.1016/s0198-8859(99)00156-1. View

Gajewski T, Meng Y, Blank C, Brown I, Kacha A, Kline J . Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006; 213:131-45. DOI: 10.1111/j.1600-065X.2006.00442.x. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

10.

Brossard C, Semichon M, Trautmann A, Bismuth G . CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol. 2003; 170(9):4623-9. DOI: 10.4049/jimmunol.170.9.4623. View

11.

Dasu T, Qualls J, Tuna H, Raman C, Cohen D, Bondada S . CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett. 2008; 119(1-2):103-13. PMC: 2604124. DOI: 10.1016/j.imlet.2008.05.008. View

12.

Indraccolo S, Mion M, Zamarchi R, Coppola V, Calderazzo F, Amadori A . A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Clin Immunol Immunopathol. 1995; 77(3):253-61. DOI: 10.1006/clin.1995.1151. View

13.

Brown M, Lacey E . A ligand for CD5 is CD5. J Immunol. 2010; 185(10):6068-74. PMC: 2996635. DOI: 10.4049/jimmunol.0903823. View

14.

Gimferrer I, Farnos M, Calvo M, Mittelbrunn M, Enrich C, Sanchez-Madrid F . The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J Biol Chem. 2002; 278(10):8564-71. DOI: 10.1074/jbc.M209591200. View

15.

Smith C, Wilson N, Waithman J, Villadangos J, Carbone F, Heath W . Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol. 2004; 5(11):1143-8. DOI: 10.1038/ni1129. View

16.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

17.

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

18.

Mangsbo S, Sandin L, Anger K, Korman A, Loskog A, Totterman T . Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010; 33(3):225-35. DOI: 10.1097/CJI.0b013e3181c01fcb. View

19.

Bamberger M, Santos A, Goncalves C, Oliveira M, James J, Moreira A . A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase. J Biol Chem. 2011; 286(35):30324-30336. PMC: 3162391. DOI: 10.1074/jbc.M111.230102. View

20.

Gary-Gouy H, Harriague J, Dalloul A, Donnadieu E, Bismuth G . CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J Immunol. 2001; 168(1):232-9. DOI: 10.4049/jimmunol.168.1.232. View